T n krishnan biography of christopher
Dr. Balaji Krishnan
Professor | Vice-Provost, International Affairs
Office
371A Administration Building
Office Hours
By Appointment
Biography
Dr. Balaji Krishnan is currently the Vice-Provost of International Affairs and Professor of Marketing in the Department of Marketing and Supply Chain Management in the Fogelman College of Business & Economics at The University of Memphis. Dr. Krishnan has 10 years as an academic administrator. Dr. Krishnan has 25 years of experience in marketing research, consulting and marketing education. Dr. Krishnan has consulted with small businesses as well as multinationals in India and the US. He has also consulted with firms in various industries. He has taught in the Doctoral, Masters and Undergraduate programs. Dr. Krishnan received his Bachelors degree in Electronics and Telecommunication Engineering and his Masters degree in Marketing from India. He received his PhD in Business Administration from Louisiana State University.
Teaching
He currently teaches Global Strategic Marketing in the MBA and EMBA programs. He also teaches the Advanced Consumer Behavior Seminar in the Doctoral Program.
Service
Represented the department at the Faculty Senate.
Was the Director of MBA Programs since 2012.
Research
Sarkar, Aditi, M. S. Balaji and Balaji Krishnan, “How Customers Cope with Service Failure? A Study of Brand Reputation and Customer Satisfaction.” Forthcoming, Journal of Business Research.
Krishnan, Balaji C., Sujay Dutta, and Subhash Jha (2013), “Effectiveness of Exaggerated Advertised Reference Prices: The Role of Decision Time Pressure,” Journal of Retailing, 89 (1), 105 -113.
Billing, Tejinder K., Rabi S. Bhagat, Emin Babakus, Balaji C. Krishnan, David L. Ford, B.N. Srivastava, Ujaval Rajadhyaksha, Mannsoo Shin, Ben Kuo, Catherine Kwantes, Bernadette Setiadi, Aizzat Mohd. Nasurdin (2012), “Work-Family Conflict, Psychological Strain and Work Outcomes: The Mod
Sriram Krishnan's Profile
Chris Pollett > Students >
Sriram
( Print View )
[Bio]
[CS 280 Project Blog]
[CS280 Proposal]
[Project Screen captures]
[Download Source code [zip]]
I am a web developer Seeking a position as a programmer in the field of Computer Science that would provide me an opportunity to excel in a dynamic environment, enhance my technical and interpersonal skills.I have good work experience in developing web-applications. Please have a look at my work history below
EDUCATION
Master of Science, Computer Science Spring 2008-2009
San Jose State University,San Jose,CA CGPA: 3.80 on a scale of 4
Bachelor of Engineering, Computer Science Aug 2002-Apr 2006
Anna University, TN, India. CGPA: 8.51 on a scale of 10
WORK EXPERIENCE
Web Developer Intern-Watercooler-inc, January 2009- Till Date
Web developer intern for Watercooler-inc. Watercooler provides the most extensive network of online fan
communities around sports and TV entertainment spanning the TVLoop.com website and top social networking sites
including Facebook, MySpace, Bebo, Friendster, and hi5.
Web Editor-San Jose State University, September 2008- May 2009
Web Editor for SJSU's Academic technology department. This team aims in converting the web sites of various
departments at SJSU to OpenCMS7 format and to make the web pages adhere to accessibility standards.
Analyst- Verizon Data Services INDIA. June 2007-Jan 2008
Web developer Analyst for Verizon's On-line Ordering system-Verizon.com (ASP.NET,C# web development). Lead a
team of six members for one of Verizon.com's biggest initiative-One click
Software Engineer-Verizon Data Services INDIA. June 2006-May Drug-Eluting Resorbable Scaffold versus Angioplasty for Infrapopliteal Artery Disease
Background: Among patients with chronic limb-threatening ischemia (CLTI) and infrapopliteal artery disease, angioplasty has been associated with frequent reintervention and adverse limb outcomes from restenosis. The effect of the use of drug-eluting resorbable scaffolds on these outcomes remains unknown.
Methods: In this multicenter, randomized, controlled trial, 261 patients with CLTI and infrapopliteal artery disease were randomly assigned in a 2:1 ratio to receive treatment with an everolimus-eluting resorbable scaffold or angioplasty. The primary efficacy end point was freedom from the following events at 1 year: amputation above the ankle of the target limb, occlusion of the target vessel, clinically driven revascularization of the target lesion, and binary restenosis of the target lesion. The primary safety end point was freedom from major adverse limb events at 6 months and from perioperative death.
Results: The primary efficacy end point was observed (i.e., no events occurred) in 135 of 173 patients in the scaffold group and 48 of 88 patients in the angioplasty group (Kaplan-Meier estimate, 74% vs. 44%; absolute difference, 30 percentage points; 95% confidence interval [CI], 15 to 46; one-sided P<0.001 for superiority). The primary safety end point was observed in 165 of 170 patients in the scaffold group and 90 of 90 patients in the angioplasty group (absolute difference, -3 percentage points; 95% CI, -6 to 0; one-sided P<0.001 for noninferiority). Serious adverse events related to the index procedure occurred in 2% of the patients in the scaffold group and 3% of those in the angioplasty group.
Conclusions: Among patients with CLTI due to infrapopliteal artery disease, the use of an everolimus-eluting resorbable scaffold was superior to angioplasty with respect to the primary efficacy end point. (Funded by Abbott; LIFE-BTK ClinicalTrials.g
Tm krishna siblings 
.
Tm krishna concert schedule
Drug-Eluting Resorbable Scaffold versus Angioplasty for Infrapopliteal Artery Disease
Background: Among patients with chronic limb-threatening ischemia (CLTI) and infrapopliteal artery disease, angioplasty has been associated with frequent reintervention and adverse limb outcomes from restenosis. The effect of the use of drug-eluting resorbable scaffolds on these outcomes remains unknown.
Methods: In this multicenter, randomized, controlled trial, 261 patients with CLTI and infrapopliteal artery disease were randomly assigned in a 2:1 ratio to receive treatment with an everolimus-eluting resorbable scaffold or angioplasty. The primary efficacy end point was freedom from the following events at 1 year: amputation above the ankle of the target limb, occlusion of the target vessel, clinically driven revascularization of the target lesion, and binary restenosis of the target lesion. The primary safety end point was freedom from major adverse limb events at 6 months and from perioperative death.
Results: The primary efficacy end point was observed (i.e., no events occurred) in 135 of 173 patients in the scaffold group and 48 of 88 patients in the angioplasty group (Kaplan-Meier estimate, 74% vs. 44%; absolute difference, 30 percentage points; 95% confidence interval [CI], 15 to 46; one-sided P<0.001 for superiority). The primary safety end point was observed in 165 of 170 patients in the scaffold group and 90 of 90 patients in the angioplasty group (absolute difference, -3 percentage points; 95% CI, -6 to 0; one-sided P<0.001 for noninferiority). Serious adverse events related to the index procedure occurred in 2% of the patients in the scaffold group and 3% of those in the angioplasty group.
Conclusions: Among patients with CLTI due to infrapopliteal artery disease, the use of an everolimus-eluting resorbable scaffold was superior to angioplasty with respect to the primary efficacy end point. (Funded by Abbott; LIFE-BTK ClinicalTrials.g
.